94 filings
Page 2 of 5
D
vqm1n6
17 Oct 23
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
4:05pm
6-K
rcyubpoq 185uq
12 Oct 23
Current report (foreign)
8:00am
6-K
33hpq
4 Oct 23
Current report (foreign)
7:24am
6-K
0ynxa te9fc6
12 Sep 23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
7:49am
6-K
tln1s
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
e3h6kqqww2dz5
3 Aug 23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
8:39am
6-K
8yr5kh54fuhhgkvbp
18 Jul 23
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
7:58am
6-K
49vmzsl sqv
14 Jun 23
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
8:00am
6-K
b9uk2coxsvn
4 May 23
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
7:56am
6-K
pknzad746duzyow
21 Apr 23
Current report (foreign)
4:30pm
6-K
w6ku21xcsqjee0do
19 Apr 23
Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
8:32am
424B3
vapo ofjt7r
31 Mar 23
Prospectus supplement
4:04pm
EFFECT
fv13sm
30 Mar 23
Notice of effectiveness
12:00am
CORRESP
chzndy
28 Mar 23
Correspondence with SEC
12:00am
UPLOAD
rzm2attx9kh8pt ba2
28 Mar 23
Letter from SEC
12:00am
F-1
ju296p5ji 3r
22 Mar 23
Registration statement (foreign)
9:40am
D
57tmah iq62qxzc
15 Mar 23
$4.00 mm in equity / options / securities to be acquired, sold $4.00 mm, 1 investor
4:14pm
6-K
2xfntn
10 Mar 23
Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
5:21pm
6-K
14cg6i 2ah8
7 Mar 23
Current report (foreign)
7:45am